Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)

被引：0

作者：

Liu, S. V. ^{[1
]}

De Braud, F. ^{[2
]}

Drilon, A. ^{[3
]}

Doebele, R. C. ^{[4
]}

Patel, M. R. ^{[5
]}

Cho, B. C. ^{[6
]}

Ahn, M. J. ^{[7
]}

Chiu, C. H. ^{[8
]}

Farago, A. F. ^{[9
]}

Goto, K. ^{[10
]}

Lee, J. ^{[7
]}

Ohe, Y. ^{[11
]}

Ou, S. H. I. ^{[12
]}

Cassier, P. ^{[13
]}

Tan, D. S. W. ^{[14
]}

Otterson, G. A. ^{[15
,16
]}

Veronese, L. ^{[17
]}

Osborne, S. ^{[17
]}

Simmons, B. ^{[18
]}

Siena, S. ^{[19
,20
]}

机构：

[1] Georgetown Univ, Washington, DC 20057 USA

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[4] Univ Colorado, Aurora, CO USA

[5] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA

[6] Yonsei Canc Ctr, Seoul, South Korea

[7] Sungkyunkwan Univ, Div Hematol Oncol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea

[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan

[9] Massachusetts Gen Hosp, Boston, MA 02114 USA

[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[11] Natl Canc Ctr, Tokyo, Japan

[12] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA

[13] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[14] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore

[15] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA

[16] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA

[17] F Hoffmann La Roche Ltd, Basel, Switzerland

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

[20] Metropolitano Niguarda, Niguarda Canc Ctr, Grande Osped, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷 / 04期

关键词：

D O I：

10.1016/j.annonc.2021.01.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：577 / 577

页数：1

共 50 条

[1] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: of response by line of therapy
Liu, S. V.
De Braud, F.
Drilon, A.
Doebele, R. C.
Patel, M. R.
Cho, B. C.
Ahn, M-J.
Chiu, C-H.
Farago, A. F.
Goto, K.
Lee, J.
Ohe, Y.
Ou, S-H. I.
Cassier, P.
Tan, D. S. W.
Otterson, G. A.
Veronese, L.
Osborne, S.
Simmons, B.
Siena, S.
ANNALS OF ONCOLOGY, 2020, 31 : S472 - S473
[2] Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours
Lassen, Ulrik
LANCET ONCOLOGY, 2020, 21 (02): : 193 - 194
[3] Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Ahn, M.
Cho, B. C.
Siena, S.
Drilon, A.
De Braud, F.
Krebs, M.
John, T.
Karapetis, C.
Johnson, A.
Chow-Maneval, E.
Multani, P.
Doebele, R.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1783 - S1783
[4] Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
Dziadziuszko, R.
Siena, S.
Tan, D. S. W.
Cho, B. C.
Ahn, M-J.
Goto, K.
Garrido-Lopez, P.
Farago, A. F.
Loong, H. H. F.
Tosi, D.
John, T.
Wolf, J.
Chiu, C-H.
Liu, S. V.
Patel, M. R.
Drilon, A.
Pitcher, B.
Simmons, B.
Doebele, R. C.
ANNALS OF ONCOLOGY, 2020, 31 : S833 - S834
[5] Entrectinib Approved for NTRK Fusion-Positive Solid Tumors and ROS1-Rearranged Non-Small Cell Lung Cancer
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 610 - 610
[6] Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Doebele, R.
Ahn, M.
Siena, S.
Drilon, A.
Krebs, M.
Lin, C.
De Braud, F.
John, T.
Tan, D.
Seto, T.
Dziadziuszko, R.
Arkenau, H.
Barlesi, F.
Rolfo, C.
Wolf, J.
Chow-Maneval, E.
Multani, P.
Cui, N.
Riehl, T.
Cho, B. C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S321 - S322
[7] Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
Cho, Byoung Chul
Chiu, Chao-Hua
Massarelli, Erminia
Buchschacher, Gary L.
Goto, Koichi
Overbeck, Tobias R.
Loong, Herbert H. F.
Chee, Cheng E.
Garrido, Pilar
Dong, Xiaorong
Fan, Yun
Lu, Shun
Schwemmers, Sven
Bordogna, Walter
Zeuner, Harald
Osborne, Stuart
John, Thomas
LUNG CANCER, 2024, 188
[8] Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases
Paz-Ares, L.
Dziadziuszko, R.
Drilon, A.
John, T.
Krebs, M.
Demetri, G.
Shaw, A.
Siena, S.
Wolf, J.
Farago, A.
Simmons, B.
Ye, C.
Huang, X.
Doebele, R.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S305 - S305
[9] Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases
Paz-Ares, Luis
Dziadziuszko, Rafal
Drilon, Alexander
John, Thomas
Krebs, Matthew
Demetri, George
Shaw, Alice T.
Siena, Salvatore
Wolf, Juergen
Farago, Anna F.
Simmons, Brian
Pitcher, Bethany
Huang, Xinhui
Doebele, Robert
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 235 - 235
[10] Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
Paz-Ares, L.
Barlesi, F.
Siena, S.
Ahn, M-J
Drilon, A.
Conley, A.
Rolfo, C.
Wolf, J.
Seto, T.
Doebele, R.
Kapre, A.
Chen, D.
McCallum, S.
Osborne, S.
Demetri, G.
ESMO OPEN, 2021, 6 (03)

← 1 2 3 4 5 →